Caitlin Fox Bell

Caitlin Fox Bell

Auto-generated profile, based on publicly available information

Caitlin Fox Bell

Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2012 in Nature
Verified
Journal Article
Open access
PDF file
JNJayakrishnan Nandakumar
Jayakrishnan Nandakumar
CBCaitlin F. Bell
Caitlin F. Bell
IWIna Weidenfeld
Ina Weidenfeld
AZArthur J. Zaug
Arthur J. Zaug
LLLeslie A. Leinwand
Leslie A. Leinwand
TCThomas R. Cech
Thomas R. Cech
Using separation-of-function mutations of TPP1 that inhibit telomerase binding while maintaining telomere capping, a region on the surface of TPP1, the TEL patch, is identified and found to be required for both binding telomerase and enhancing its processivity. The human chromosomal telomere-binding protein TPP1 protein binds telomeric single-stranded DNA and has an essential role in protecting chromosome ends. It is believed to both recruit and stimulate telomerase, the enzyme that replicates chromosome ends. Thomas Cech and colleagues show, using separation-of-function mutants of TPP1, that telomerase binding and telomere capping are independent functions. These mutants identify a small patch of amino acids on the surface of TPP1—the TEL patch—that is required both for binding telomerase and promoting its action. Telomerase is overexpressed in many cancers, making it a prime target for drug development. As it has been proven difficult to inhibit telomerase itself, the TEL patch provides a promising new strategy for anticancer therapy. Human chromosome ends are capped by shelterin, a protein complex that protects the natural ends from being recognized as sites of DNA damage and also regulates the telomere-replicating enzyme, telomerase1,2,3. Shelterin includes the heterodimeric POT1–TPP1 protein, which binds the telomeric single-stranded DNA tail4,5,6,7,8,9. TPP1 has been implicated both in recruiting telomerase to telomeres and in stimulating telomerase processivity (the addition of multiple DNA repeats after a single primer-binding event)9,10,11,12,13,14. Determining the mechanisms of these activities has been difficult, especially because genetic perturbations also tend to affect the essential chromosome end-protection function of TPP1 (refs 15, 16, 17). Here we identify separation-of-function mutants of human TPP1 that retain full telomere-capping function in vitro and in vivo, yet are defective in binding human telomerase. The seven separation-of-function mutations map to a patch of amino acids on the surface of TPP1, the TEL patch, that both recruits telomerase to telomeres and promotes high-processivity DNA synthesis, indicating that these two activities are manifestations of the same molecular interaction. Given that the interaction between telomerase and TPP1 is required for telomerase function in vivo, the TEL patch of TPP1 provides a new target for anticancer drug development.

30 November 2018 in Science
Verified
Journal Article
Closed access
PDF file
JAJulien Ablain
Julien Ablain
MXMengshu Xu
Mengshu Xu
HRHarriet Rothschild
Harriet Rothschild
RJRichard C. Jordan
Richard C. Jordan
JMJeffrey K. Mito
Jeffrey K. Mito
IYIwei Yeh
Iwei Yeh
Hunting and fishing for cancer genes: Mucosal melanoma is a rare, but deadly, form of melanoma that occurs in sun-protected tissues. Little is known about the genetic alterations that drive the growth of these tumors. Ablain et al. sequenced mucosal melanomas from 43 patients and found that a substantial fraction showed inactivation or loss of SPRED1 , a gene that encodes a negative regulator of RAS–MAPK (mitogen-activated protein kinase) signaling. Using a platform called MAZERATI (Modeling Approach in Zebrafish for Rapid Tumor Initiation), they discovered that SPRED1 loss may help explain the poor response of melanoma patients to drugs that inhibit the KIT tyrosine kinase. The results suggest that a combination of KIT inhibitors and drugs that inhibit MAPK signaling may be more effective. Science , this issue p. 1055

11 April 2023 in JACC: Cardiooncology
Verified
Journal Article
Open access
CBCaitlin F. Bell
Caitlin F. Bell
XLXiudong Lei
Xiudong Lei
AHAllen Haas
Allen Haas
RBRichard A. Baylis
Richard A. Baylis
HGHua Gao
Hua Gao
NLNicholas Leeper
Nicholas Leeper
Cardiovascular disease (CVD) and cancer share several risk factors. Although preclinical models show that various types of CVD can accelerate cancer progression, clinical studies have not determined the impact of atherosclerosis on cancer risk. The objective of this study was to determine whether CVD, especially atherosclerotic CVD, is independently associated with incident cancer. Using IBM MarketScan claims data from over 130 million individuals, 27 million cancer-free subjects with a minimum of 36 months of follow-up data were identified. Individuals were stratified by presence or absence of CVD, time-varying analysis with multivariable adjustment for cardiovascular risk factors was performed, and cumulative risk of cancer was calculated. Additional analyses were performed according to CVD type (atherosclerotic vs nonatherosclerotic) and cancer subtype. Among 27,195,088 individuals, those with CVD were 13% more likely to develop cancer than those without CVD (HR: 1.13; 95% CI: 1.12-1.13). Results were more pronounced for individuals with atherosclerotic CVD (aCVD), who had a higher risk of cancer than those without CVD (HR: 1.20; 95% CI: 1.19-1.21). aCVD also conferred a higher risk of cancer compared with those with nonatherosclerotic CVD (HR: 1.11; 95% CI: 1.11-1.12). Cancer subtype analyses showed specific associations of aCVD with several malignancies, including lung, bladder, liver, colon, and other hematologic cancers. Individuals with CVD have an increased risk of developing cancer compared with those without CVD. This association may be driven in part by the relationship of atherosclerosis with specific cancer subtypes, which persists after controlling for conventional risk factors.

13 September 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SBSharika Bamezai
Sharika Bamezai
YZYapei Zhang
Yapei Zhang
MKManisha Kumari
Manisha Kumari
MLMozhgan Lotfi
Mozhgan Lotfi
TATom Alsaigh
Tom Alsaigh
NLNicholas Leeper
Nicholas Leeper
Atherosclerosis is an inflammatory disorder responsible for cardiovascular disease. Reactivation of efferocytosis, the phagocytic removal of cells by macrophages, has emerged as a translational target for atherosclerosis. Systemic blockade of the key ‘don’t-eat-me’ molecule, CD47, triggers the engulfment of apoptotic vascular tissue and potently reduces plaque burden. However, it also induces red blood cell clearance, leading to anemia. To overcome this, we previously developed a macrophage-specific nanotherapy loaded with a chemical inhibitor that promotes efferocytosis. Because it was found to be safe and effective in murine studies, we aimed to advance our nanoparticle into a porcine model of atherosclerosis. Here, we demonstrate that production can be scaled without impairing nanoparticle function. At an early stage of disease, we find our nanotherapy reduces apoptotic cell accumulation and inflammation in the atherosclerotic lesion. Notably, this therapy does not induce anemia, highlighting the translational potential of targeted macrophage checkpoint inhibitors.

11 September 2023 in Biomaterials
Verified
Journal Article
Closed access
MSMartin Karl Schneider
Martin Karl Schneider
JWJames Wang
James Wang
AKAris Kare
Aris Kare
SAShaunak S. Adkar
Shaunak S. Adkar
DSDarren Salmi
Darren Salmi
KFKatherine W. Ferrara
Katherine W. Ferrara

1 February 2018 in Surgery
Verified
Journal Article
Closed access
CBCaitlin F. Bell
Caitlin F. Bell
MWMathew M. Warrick
Mathew M. Warrick
KGKathleen C. Gallagher
Kathleen C. Gallagher
NBNaira Baregamian
Naira Baregamian